计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| V422101-1ml |
1ml |
现货 ![]() |
|
| 别名 | Vipivotide 四西坦 (PSMA-617) |
|---|---|
| 英文别名 | 1702967-37-0 | Vipivotide tetraxetan | s8670 | PSMA617 | PSMA-617 | Sodium phosphate monobasic monohydrate, BioXtra, for molecular biology, >=99.5% (T) | NACLO3 | -LYSINE, N2-((((1S)-1,3-DICARBOXYPROPYL)AMINO)CARBONYL)-N6-(3-(2-NAPHTHALENYL)-N-((TRANS-4-( |
| 规格或纯度 | Moligand™, 10mM in Water |
| 英文名称 | Vipivotide tetraxetan (PSMA-617) |
| 生化机理 | Vipivotide tetraxetan(PSMA-617)是一种化学修饰的 PSMA(前列腺特异性膜抗原)抑制剂,其 Ki 值为 0.37 nM。 |
| 储存温度 | -80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 叶酸水解酶(前列腺特异性膜抗原)抑制剂 1 |
| 产品介绍 |
Vipivotide tetraxetan (PSMA-617) 是一种化学修饰的 PSMA(prostate-specific membrane antigen) 抑制剂,Ki值为0.37 nM。 Information Vipivotide tetraxetan (PSMA-617) is a chemically modified PSMA(prostate-specific membrane antigen) inhibitor with a Ki of 0.37 nM. Targets PSMA (Cell-free assay) 0.37 nM(Ki) In vitro PSMA-617 demonstrates high radiolytic stability for at least 72 h. A high inhibition potency (equilibrium dissociation constant Ki = 2.34 ± 2.94 nM on LNCaP; Ki = 0.37 ± 0.21 nM enzymatically determined) and highly efficient internalization into LNCaP cells are demonstrated. In vivo The small-animal PET measurements show high tumor-to-background contrasts as early as 1 h after injection. In vivo distribution reveals specific uptake in LNCaP tumors and in the kidneys 1 h after injection. With regard to therapeutic use, PSMA-617 exhibits a rapid clearance from the kidneys from 113.3 ± 24.4 at 1 h to 2.13 ± 1.36 percentage injected dose per gram at 24 h. The favorable pharmacokinetics of the molecule leads to tumor-to-background ratios of 1,058 (tumor to blood) and 529 (tumor to muscle), respectively,24 h after injection. Cell Research(from reference) Cell lines:PSMA-positive LNCaP cell line Concentrations:0–5000 nM Incubation Time:1 h |
| ALogP | -11.549 |
|---|---|
| HBD Count | 5 |
| Rotatable Bond | 27 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | (2S)-2-[[(1S)-1-carboxy-5-[[(2S)-3-naphthalen-2-yl-2-[[4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]methyl]cyclohexanecarbonyl]amino]propanoyl]amino]pentyl]carbamoylamino]pentanedioic acid |
| INCHI | 1S/C49H71N9O16/c59-40(28-55-17-19-56(29-42(62)63)21-23-58(31-44(66)67)24-22-57(20-18-55)30-43(64)65)51-27-32-8-12-35(13-9-32)45(68)52-39(26-33-10-11-34-5-1-2-6-36(34)25-33)46(69)50-16-4-3-7-37(47(70)71)53-49(74)54-38(48(72)73)14-15-41(60)61/h1-2,5-6,10-11,25,32,35,37-39H,3-4,7-9,12-24,26-31H2,(H,50,69)(H,51,59)(H,52,68)(H,60,61)(H,62,63)(H,64,65)(H,66,67)(H,70,71)(H,72,73)(H2,53,54,74)/t32?,35?,37-,38-,39-/m0/s1 |
| InChi Key | JBHPLHATEXGMQR-VLOIPPKDSA-N |
| Smiles | C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCCC(C(=O)O)NC(=O)NC(CCC(=O)O)C(=O)O |
| Isomeric SMILES | C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@@H](CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O |
| PubChem CID | 122706786 |
| 分子量 | 1042.14 |
| DMSO(mg / mL) Max Solubility | -1 |
|---|---|
| DMSO(mM) Max Solubility | -0.959563974130155 |
| Water(mg / mL) Max Solubility | 100 |
| Water(mM) Max Solubility | 95.9563974130155 |
| 分子量 | 1042.099 g/mol |
| XLogP3 | -8.200 |
| 氢键供体数Hydrogen Bond Donor Count | 11 |
| 氢键受体数Hydrogen Bond Acceptor Count | 20 |
| 可旋转键计数Rotatable Bond Count | 27 |
| 精确质量Exact Mass | 1041.5 Da |
| 单同位素质量Monoisotopic Mass | 1041.5 Da |
| 拓扑极表面积Topological Polar Surface Area | 365.000 Ų |
| 重原子数Heavy Atom Count | 74 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1870.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 3 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |